Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

Benin accepts TRIPS protocol on affordable medicines

24 November 2016 Benin yesterday accepted the 2005 protocol amending the World Trade Organization’s (WTO) agreement on TRIPS, a protocol intended to ease poorer WTO members’ access to affordable medicines.

Genetics

Nagoya Protocol: searching for living gold

28 November 2014 Does the coming into force of the Nagoya Protocol represent an overdue step in the right direction towards fairness, or more red tape and unattainable expectations? Charles Brabin, a non-practising barrister, sifts through the complexities.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features